ReviewMolecular nutrition & food research2026
The Evolving Therapeutic Landscape of Gallic Acid: A Review of Mechanistic Insights and Clinical Potential.
Review in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Gallic acid (GA), a plant-derived phenolic compound, is evolving from a general antioxidant into a specific molecular modulator and a functional building block for advanced biomedical materials. This review synthesizes recent insights underpinned by GA's "redox duality"-its capacity to act as either a radical scavenger or a pro-oxidant. In metabolic disorders, GA reprograms cellular machinery by modulating the miR-709/Nrf2 axis, enhancing LDL clearance via LDLR/PCSK9, and targeting the incretin system. In oncology, GA exhibits context-dependent toxicity, acting as a selective pro-oxidant to induce apoptosis and synergizing with tyrosine kinase inhibitors (TKIs), though safety interactions require careful assessment. GA's expanded neuropharmacological profile includes mitigating ferroptosis via GPX4 rescue and acting as a positive allosteric modulator of Kv1.1 channels. It also potently inhibits the NLRP3 inflammasome in gouty arthritis. Beyond traditional pharmacology, recent studies highlight GA's emergence in material science, including the development of GA-based Metal-Organic Frameworks (MOFs) and functional hydrogels for osteoarthritis, kidney stone prevention, and wound healing. Despite broad bioactivity, poor bioavailability remains a significant challenge, necessitating innovative bioactive material design and rigorous clinical validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.